| Old Articles: <Older 2011-2020 Newer> |
|---|
 |
The Motley Fool
May 18, 2005
Brian Gorman |
Lilly Launches Automation Eli Lilly's drive to improve efficiency makes the company worth watching.   |
The Motley Fool
May 18, 2005
Stephen D. Simpson |
No Pain, No Gain PainCare is more than just a shell company going on an acquisition binge; there's actual potential here. Aggressive investors with a little streak of speculator in them might want to roll up their sleeves and do some due diligence. |
The Motley Fool
May 17, 2005
Charly Travers |
BioMarin Bounces Back After a stumble, one biotech firm is returning to the market's good graces. BioMarin stock has shot up 30% in the past two months and is near its 52-week high. |
The Motley Fool
May 17, 2005
Rich Smith |
Nutraceutical's Secret Ingredient If it's real-world cash you're after, and steady long-term performance in an investment, Nutraceutical just might make for a healthy supplement to your portfolio. |
Reason
May 2005
Ronald Bailey |
Aborting Plan B Barr Pharmaceuticals wants to offer its emergency contraceptive levonorgestrel, marketed as Plan B, over the counter rather than by prescription. The FDA delayed an anticipated decision on the issue indefinitely, adding another chapter to a long and heavily politicized debate. |
Reason
May 2005
Jesse Walker |
Hospital Hazing Long shifts are part of the set of barriers that limit entry to the medical profession. Whatever other reasons exist for them, they're ultimately a byproduct of occupational licensing. |
The Motley Fool
May 16, 2005
Ellen Dowling |
Merck Minds Its Manners The drug giant's handbook for its salespeople has Congress offended. Whether the committee thinks its salespeople are charismatic or just plain con artists, Merck's actions will eventually speak louder than its words for patient investors. |
The Motley Fool
May 13, 2005
Brian Gorman |
Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude. |
The Motley Fool
May 13, 2005
Karl Thiel |
Boning Up on New Drugs Are new osteoporosis therapies compelling investments, or is the field too crowded? |
The Motley Fool
May 13, 2005
Stephen D. Simpson |
Waiting for Sanofi's Next Act Sanofi-Aventis' first-quarter numbers were good. Will they soon be better? Though the stock is not the greatest idea for highly income-oriented investors, the growth-at-a-reasonable-price crowd might want to investigate further. |
| <Older 2011-2020 Newer> Return to current articles. |
